Allurion Technologies Revenue

In the year 2025, Allurion Technologies had annual revenue of $15.23M, down -52.57%. Allurion Technologies had revenue of $3.61M in the quarter ending December 31, 2025, a decrease of -35.38%.

Revenue

15.23M

Revenue Growth

-52.57%

P/S Ratio

0.69

Revenue / Employee

380.75K

Employees

Market Cap

10.50M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	15.23M	-16.88M	-52.57%
Dec 31, 2024	32.11M	-21.36M	-39.94%
Dec 31, 2023	53.47M	-10.74M	-16.73%
Dec 31, 2022	64.21M	25.97M	67.91%
Dec 31, 2021	38.24M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Biotricity	15.45M
ADM Tronics Unlimited	3.41M
QHSLab	2.69M
Kelyniam Global	2.67M
BioElectronics	1.61M
Guided Therapeutics	767.00K
ALR Technologies SG	25.54K
REMSleep Holdings	16.72K

Revenue Rankings

Allurion Technologies News

24 days ago - Allurion Technologies treats first commercial patients in the U.S. - TheFly
24 days ago - Allurion Treats First Commercial Patients in the United States, Marking Major Milestone - Business Wire
2 months ago - Allurion Technologies appeals NYSE decision to initiate delisting proceedings - TheFly
2 months ago - Allurion Advances Plan to Regain Listing Compliance - Business Wire
2 months ago - Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy - Business Wire
2 months ago - NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR) - Business Wire
2 months ago - Allurion Technologies to appeal NYSE notice of delisting - TheFly
2 months ago - Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE - Business Wire

More News